SCHEMBL26100676

SCHEMBL26100676

O=S(=O)(N1CCOCC1)N1C[C@H](c2ccccc2)C[C@@H]1CBr

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
MAPT P10636 3/20 0.39
POLB P06746 2/20 0.38
KMT2A Q03164 4/20 0.37
GAA P10253 3/20 0.37
MEN1 O00255 3/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2C9 P11712 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 4/20 0.37
MAPK1 P28482 1/20 0.37
USP2 O75604 1/20 0.36
PKM P14618 1/20 0.36
CA12 O43570 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
BRD4 O60885 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26099322 1.00 LMNA (0.40) LMNAMAPTPOLBKMT2AGAA
SCHEMBL26910574 0.88 SMN1; SMN2 (0.39) LMNAKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL26910568 0.88 SMN1; SMN2 (0.39) LMNAKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL26098035 0.84 NPC1 (0.40) LMNAMAPTPOLBKMT2AGAA
SCHEMBL26097698 0.84 NPC1 (0.40) LMNAMAPTPOLBKMT2AGAA
SCHEMBL26532480 0.84 NPC1 (0.40) LMNAMAPTPOLBKMT2AGAA
SCHEMBL30392028 0.81 LMNA (0.40) LMNAMAPTPOLBKMT2AGAA
SCHEMBL26910596 0.78 PAX8 (0.42) KMT2AALDH1A1TSHRPKMBRD4
SCHEMBL26099344 0.78 PAX8 (0.42) KMT2AALDH1A1TSHRPKMBRD4
SCHEMBL26097559 0.73 LMNA (0.48) LMNAMAPTPOLBKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016864-B2 LOX enzyme inhibiting methods and compositions ANOVIA BIOSCIENCES, INC. (US) 2024-06-25 US disclosed
US-20230390299-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES INC (US) 2023-12-07 US disclosed
WO-2023076567-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390299-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS LOX, LOXL1, LOXL2 LMNA 363/4885MAPT 2407/4885POLB 1669/4885
US-12016864-B2 LOX enzyme inhibiting methods and compositions LOX, LOXL1, LOXL2 LMNA 518/4885MAPT 2678/4885POLB 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.